All In Biotech

Drug Trial Radar · NCT01127581

Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery

Phase III, Double-blind, Randomized, Multicenter Study of Exogenous Prostaglandin Comparing the Efficacy & Safety of the MVI 200 mcg Versus the Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery in Pregnant Women at Term

Last checked: Nov 20, 2026Latest source record: May 1, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,358 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,358

Actual

Start

Sep 2010

Primary completion

Mar 2012

Study completion Mar 2012

Sponsor

Lead sponsor
Ferring PharmaceuticalsIndustry
Sponsor type
Industry
First posted
May 21, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether the Misoprostol Vaginal Insert (MVI) 200 microgram (mcg) can decrease the time to vaginal delivery compared to the Dinoprostone Vaginal Insert (DVI) 10 milligram (mg) in pregnant women requiring cervical ripening and induction of labor.

Conditions

  • Reducing Time to Vaginal Delivery
  • Cervical Ripening
  • Induction of Labor

Interventions

  • MVI 200Drug

    Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.

  • Dinoprostone Vaginal Insert (DVI)Drug

    Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Vaginal Delivery During the First Hospital AdmissionTime frame: Interval from study drug administration to vaginal delivery (average 24 hours)
  2. Incidence of Cesarean Delivery During the First Hospital AdmissionTime frame: Interval from study drug administration to cesarean delivery (average 24 hours)

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • Maricopa Medical Center - District Medical Group

    Phoenix, Arizona

  • Precision Trials

    Phoenix, Arizona

  • Phoenix Perinatal Associates (Scottsdale Healthcare Shea)

    Scottsdale, Arizona

  • Watching Over Mothers and Babies Foundation

    Tucson, Arizona

  • Miller's Childrens Hospital

    Long Beach, California

  • UCI Medical Center

    Orange, California

  • The Women's Clinic of Northern Colorado

    Fort Collins, Colorado

  • Christiana Care Health System (DE Center for MFM)

    Newark, Delaware

  • University of FL College of Medicine

    Jacksonville, Florida

  • Altus Research

    Lake Worth, Florida

  • University of South Florida

    Tampa, Florida

  • Indiana University School of Medicine

    Indianapolis, Indiana

  • University of Kansas School of Medicine

    Kansas City, Kansas

  • University of Michigan Hospital

    Ann Arbor, Michigan

  • Spectrum Health

    Grand Rapids, Michigan

  • St. Louis University

    St Louis, Missouri

  • St. Peters University Hospital

    New Brunswick, New Jersey

  • University of New Mexico/New Mexico Health Science Center

    Albuquerque, New Mexico

  • Duke University Medical Center

    Durham, North Carolina

  • East Carolina University, Brody School of Medicine

    Greenville, North Carolina

  • Lyndhurst Gynecologic Associates

    Winston-Salem, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • Clinical Trials of America

    Eugene, Oregon

  • Drexel University College of Medicine

    Philadelphia, Pennsylvania

  • Temple University School of Medicine

    Philadelphia, Pennsylvania

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • University Medical Group/Greenville Hospital System

    Greenville, South Carolina

  • UT College of Medicine Chattanooga, Erlanger Health System

    Chattanooga, Tennessee

  • High Risk Obstetrical Consultants, PLLC

    Knoxville, Tennessee

  • Research Memphis Associates

    Memphis, Tennessee

  • University of Texas Health Sciences Center at Houston

    Houston, Texas

  • Salt Lake Women's Center, PC

    Sandy City, Utah

  • Marshfield Clinic Research Foundation

    Marshfield, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.